Aims of TRIDENT
TRIDENT is a prospective, multi-center observational cohort study enrolling adults with diabetes who are undergoing clinically indicated kidney biopsy as part of routine clinical care. Kidney tissue obtained at biopsy, together with paired blood and urine samples, enables comprehensive molecular, genetic, and biomarker analyses at scale.
By integrating kidney histopathology with high-throughput genomic and biomarker profiling and longitudinal clinical outcomes, TRIDENT aims to distinguish patients at highest risk for rapid kidney function decline and progression to kidney failure from those with more stable disease. This tissue-anchored design enables direct identification of disease-driving biological mechanisms that cannot be resolved through clinical data alone.
Participants are enrolled across multiple clinical sites within the TRIDENT consortium using standardized protocols to ensure consistency of data and sample collection. The overarching aim of TRIDENT is to enable biologically informed risk stratification, improve prediction of disease progression, and support the development of targeted therapeutic strategies to prevent diabetes-related kidney failure.
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Report Accessibility Issues and Get Help | Privacy Policy | Site Design: PMACS Web Team.